[CAS NO. 5088-90-4] Liensinine Diperchlorate
PRODUCTS SPECIFICATIONS [5088-90-4]
DESCRIPTION [5088-90-4]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 811.66 |
| Molecular Formula | C37H44Cl2N2O14 |
| SMILES | O=Cl(=O)(O)=O.CN1[C@@H](C2=CC(OC3=CC(C[C@@H]4C5=CC(OC)=C(OC)C=C5CCN4C)=CC=C3O)=C(OC)C=C2CC1)CC6=CC=C(O)C=C6.O=Cl(=O)(O)=O |
5 Publications Citing Use of MCE
Summary
Liensinine Diperchlorate is a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn. Liensinine Diperchlorate inhibits late-stage autophagy / mitophagy through blocking autophagosome-lysosome fusion. Liensinine Diperchlorate has a wide range of biological activities, including anti-arrhythmias, anti-hypertension, anti-pulmonary fibrosis, relaxation on vascular smooth muscle, etc [1] .
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00100074 | National Institute on Drug Abuse (NIDA) |
Amphetamine-Related Disorders
|
September 2004 | Phase 1 |
| NCT00519259 | National Institute on Drug Abuse (NIDA) |
Methamphetamine Dependence
|
February 2006 | Phase 1 |
| NCT00664703 | Yaupon Therapeutics|National Institute of Mental Health (NIMH) |
Attention Deficit Disorder With Hyperactivity
|
July 2008 | Phase 2 |
| NCT00439504 | National Institute on Drug Abuse (NIDA) |
Methamphetamine Dependence
|
Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 62.5 mg/mL ( 77.00 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.2320 mL | 6.1602 mL | 12.3204 mL |
| 5 mM | 0.2464 mL | 1.2320 mL | 2.4641 mL |
| 10 mM | 0.1232 mL | 0.6160 mL | 1.2320 mL |